SBIR/STTR Research Award

A novel compound to selectively protect normal tissues from chemotherapy

Award identifier 09dfdc4a85d33290d745215df0cc5bfe895b7a921e155d489ee69e2d901fff90Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$147,830

Program and phase

SBIR · Phase I

Award year

2010

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
PERSCITUS BIOSCIENCES, LLC
Proposal award date
Not reported
Contract end date
Not reported
UEI
Not reported
Solicitation number
PHS2010-2
Topic code
NCI

Research abstract

DESCRIPTION (provided by applicant): The successful treatment of human cancer depends on the ability to find treatments that kill tumor cells without impacting normal tissue significantly. An alternative approach is to selectively protect normal tissue from the toxic effects of chemotherapy while leaving the tumor cells vulnerable. Perscitus Biosciences, LLC has successfully synthesized a compound that we hypothesize will increase the protective molecule glutathione in normal tissue but not tumor tissue. Glutathione is known to protect against reactive oxygen species including those generated during the treatment of cancer with chemotherapy. In this project, we will examine the ability of the compound to selectively increase glutathione levels in normal tissue - and not tumor tissue - to protect against chemotherapy- induced toxicity. Analytic methods will be developed in conjunction with the Ohio State University Comprehensive Cancer Center Pharmacoanalytic Laboratory to allow us to measure the different metabolic steps that this compound must undergo to generate glutathione. If successful, this compound could significantly decrease much of the toxicity seen with common chemotherapy treatments of cancer. Importantly, protection of the normal tissue will allow escalation of the doses used in cancer treatment, potentially improving the ability to treat cancer effectively. PUBLIC HEALTH RELEVANCE: Over 500,000 people die from cancer in the U.S. each year. To improve the treatment of cancer, treatment regimens are needed with improved tolerability and effectiveness. The compound presented in this project has the potential to both decrease the side effects associated with cancer treatment as well as improve the anti-cancer effect.

Technology keywords

Not reported

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.